Literature DB >> 22936999

Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain.

Adi D Sabag1, Julia Bode, Dorit Fink, Boaz Kigel, Wilfried Kugler, Gera Neufeld.   

Abstract

Class-3 semaphorins are secreted axon guidance factors. Some of these semaphorins have recently been characterized as suppressors of tumor progression. To determine if class-3 semaphorins can be used to inhibit the development of glioblastoma-multiforme tumors, we expressed recombinant sema-3A, 3B, 3D, 3E, 3F or 3G in U87MG glioblastoma cells. Sema3A and sema3B expressing cells contracted and changed shape persistently while cells expressing other semaphorins did not. Sema3A and sema3F differed from other semaphorins including sema3B as they also inhibited the proliferation of the cells and the formation of soft agar colonies. With the exception of sema3G and sema3B, expression of these semaphorins in U87MG cells inhibited significantly tumor development from subcutaneously implanted cells. Strong inhibition of tumor development was also observed following implantation of U87MG cells expressing each of the class-3 semaphorins in the cortex of mouse brains. Sema3D and sema3E displayed the strongest inhibitory effects and their expression in U373MG or in U87MG glioblastoma cells implanted in the brains of mice prolonged the survival of the mice by more then two folds. Furthermore, most of the mice that died prior to the end of the experiment did not develop detectable tumors and many of the mice survived to the end of the experiment. Most of the semaphorins that we have used here with the exception of sema3D were characterized previously as inhibitors of angiogenesis. Our results indicate that sema3D also functions as an inhibitor of angiogenesis and suggest that the anti-tumorigenic effects are due primarily to inhibition of tumor angiogenesis. These results indicate that class-3 semaphorins such as sema3D and sema3E could perhaps be used to treat glioblastoma patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22936999      PMCID: PMC3427296          DOI: 10.1371/journal.pone.0042912

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  30 in total

1.  Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma.

Authors:  Andrea Salmaggi; Marica Eoli; Simona Frigerio; Antonio Silvani; Maurizio Gelati; Elena Corsini; Giovanni Broggi; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

Review 2.  Angiogenesis assays: a critical overview.

Authors:  Robert Auerbach; Rachel Lewis; Brenda Shinners; Louis Kubai; Nasim Akhtar
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

Review 3.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation.

Authors:  P B Vermeulen; G Gasparini; S B Fox; M Toi; L Martin; P McCulloch; F Pezzella; G Viale; N Weidner; A L Harris; L Y Dirix
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

4.  Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice.

Authors:  RuiHua Xiang; Albert R Davalos; Charles H Hensel; Xiao-Jun Zhou; Christin Tse; Susan L Naylor
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

Review 5.  The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis.

Authors:  Gera Neufeld; Tzafra Cohen; Niva Shraga; Tali Lange; Ofra Kessler; Yael Herzog
Journal:  Trends Cardiovasc Med       Date:  2002-01       Impact factor: 6.677

6.  Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors.

Authors:  T Takahashi; A Fournier; F Nakamura; L H Wang; Y Murakami; R G Kalb; H Fujisawa; S M Strittmatter
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

7.  Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates.

Authors:  L Tamagnone; S Artigiani; H Chen; Z He; G I Ming; H Song; A Chedotal; M L Winberg; C S Goodman; M Poo; M Tessier-Lavigne; P M Comoglio
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

8.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

9.  Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells.

Authors:  H Gitay-Goren; T Cohen; S Tessler; S Soker; S Gengrinovitch; P Rockwell; M Klagsbrun; B Z Levi; G Neufeld
Journal:  J Biol Chem       Date:  1996-03-08       Impact factor: 5.157

10.  Semaphorin-3F is an inhibitor of tumor angiogenesis.

Authors:  Ofra Kessler; Niva Shraga-Heled; Tali Lange; Noga Gutmann-Raviv; Edmond Sabo; Limor Baruch; Marcelle Machluf; Gera Neufeld
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

View more
  29 in total

Review 1.  Divergent roles of Plexin D1 in cancer.

Authors:  Sneha Vivekanadhan; Debabrata Mukhopadhyay
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

Review 2.  Semaphorins and plexins as therapeutic targets.

Authors:  Thomas Worzfeld; Stefan Offermanns
Journal:  Nat Rev Drug Discov       Date:  2014-08       Impact factor: 84.694

Review 3.  The role of the semaphorins in cancer.

Authors:  Gera Neufeld; Yelena Mumblat; Tatyana Smolkin; Shira Toledano; Inbal Nir-Zvi; Keren Ziv; Ofra Kessler
Journal:  Cell Adh Migr       Date:  2016-08-17       Impact factor: 3.405

Review 4.  The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.

Authors:  Changbin Zhu; Johan M Kros; Caroline Cheng; Dana Mustafa
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

5.  Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1.

Authors:  Yu-Hsuan Hung; Ming-Derg Lai; Wen-Chun Hung; Li-Tzong Chen
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

6.  Transmembrane Transporter Sema3D Serves as a Tumor Suppressor in Localized Clear Cell Renal Cell Carcinoma.

Authors:  Ruiyang Xie; Jie Wu; Bingqing Shang; Chuanzhen Cao; Xingang Bi; Hongzhe Shi; Jianzhong Shou; Youyan Guan
Journal:  J Oncol       Date:  2022-06-30       Impact factor: 4.501

Review 7.  The role of semaphorins and their receptors in vascular development and cancer.

Authors:  Chenghua Gu; Enrico Giraudo
Journal:  Exp Cell Res       Date:  2013-02-17       Impact factor: 3.905

8.  Semaphorin 3d and semaphorin 3e direct endothelial motility through distinct molecular signaling pathways.

Authors:  Haig Aghajanian; Connie Choi; Vivienne C Ho; Mudit Gupta; Manvendra K Singh; Jonathan A Epstein
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

9.  Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo.

Authors:  Hironao Nakayama; Sarah Bruneau; Nora Kochupurakkal; Silvia Coma; David M Briscoe; Michael Klagsbrun
Journal:  Sci Rep       Date:  2015-07-09       Impact factor: 4.379

10.  Plexin-B2 promotes invasive growth of malignant glioma.

Authors:  Audrey P Le; Yong Huang; Sandeep C Pingle; Santosh Kesari; Huaien Wang; Raymund L Yong; Hongyan Zou; Roland H Friedel
Journal:  Oncotarget       Date:  2015-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.